Laura Panjwani

Articles

Upcoming Approvals, Combinations Will Transform CLL Treatment

February 25th 2016

Victor Y. Yazbeck, MD, discusses the potential for venetoclax and idelalisib, both as single agents and in combination with other agents, and what questions remain regarding both therapies in CLL.

Evidence Supports Earlier Use of Radium-223, Expert Says

February 24th 2016

Fred Saad, MD, discusses treatment with radium-223 in asymptomatic patients and potential combination regimens with the radiopharmaceutical in castration-resistant prostate cancer.

With Radium-223 Leading the Way, Use of Radiopharmaceuticals Continues to Evolve

February 24th 2016

Neal Shore, MD, discusses the evolution of radiopharmaceuticals, how radium-223 works, and its potential for use in combination with other agents.

Immunotherapy Continues Rapid Advance in NSCLC

February 16th 2016

Naiyer Rizvi, MD, discusses the role of PD-L1 testing, which PD-1/PD-L1 agents have the most potential, and what is on the horizon for the use of immunotherapies in non-small cell lung cancer.

Nivolumab, Cabozantinib Offer New Second-Line Options in RCC

February 15th 2016

Toni Choueiri, MD, discusses the CheckMate-025 and METEOR trials and the potential for nivolumab and cabozantinib in the first- and second-line settings for treating renal cell carcinoma.

Melanoma Brings Immunotherapy to the Forefront, But Challenges Remain

February 9th 2016

Jeffrey S. Weber, MD, PhD, discusses the role that melanoma specialists can play in educating other oncologists, immunotherapy use for BRAF-mutated patients with melanoma, and how the use of chemotherapy may evolve as immunotherapies take the forefront.

Immunotherapy Shows Potential in Rare Melanoma Subtype

February 9th 2016

Richard Joseph, MD, discusses the challenges of treating mucosal melanoma and what oncologists need to know prior to using immunotherapies for the treatment of both mucosal and cutaneous melanomas.

Expert Discusses Next Steps With T-VEC in Melanoma

February 8th 2016

Howard L. Kaufman, MD, discusses remaining questions regarding T-VEC, the impact of the FDA approval, and its future potential.

Nivolumab Hailed as “Game Changer” in Head and Neck Cancer

February 8th 2016

Robert Ferris, MD, PhD, discusses CheckMate-141, the biggest remaining challenges in head and neck cancer, and the potential for nivolumab as a treatment of patients with the disease.

Expert Hails Ixazomib Approval as “Huge Advance” in Multiple Myeloma

February 4th 2016

Philippe Moreau, MD, discusses the significance of ixazomib and the TOURMALINE-MM1 study, as well as the benefit of an oral regimen for the treatment of patients with relapsed multiple myeloma.

Innovation, Education Critical to Optimizing Early Detection in Prostate Cancer

February 3rd 2016

E. David Crawford, MD, discusses his view of the current role for PSA testing in prostate cancer and the need for continued innovation and advancement with new screening technologies.

Combining Nivolumab With Radiation Shows Promise in Melanoma Patients With Brain Mets

February 2nd 2016

Combining nivolumab (Opdivo) with radiation therapy may provide better disease control and prolong overall survival in patients with melanoma whose disease has metastasized to the brain, compared with standard current treatment.

Wolchok on Impact of Nivolumab's Expanded Approval in Melanoma

February 2nd 2016

Jedd D. Wolchok, MD, discusses the implications of the expanded FDA approval of nivolumab, and the potential for the PD-1 inhibitor as both a single agent and as part of a combination regimen in advanced melanoma

“Hormone Holiday” Can Improve QoL for Select Patients With Prostate Cancer

February 1st 2016

Leonard G. Gomella, MD, discusses intermittent hormonal therapy for patients with prostate cancer as well as its benefits and challenges.

PD-1 Inhibitors Make Tremendous Impact in NSCLC, But Questions Remain

January 28th 2016

Renato Martins, MD, discusses what questions still remain regarding PD-L1 as a biomarker, sequencing, and how nivolumab and pembrolizumab compare head-to-head in non–small cell lung cancer.

Expert Assesses Atezolizumab in NSCLC

January 28th 2016

Chandra P. Belani, MD, discusses the impact of clinical trials examining atezolizumab and the role of PD-L1 as a predictive and prognostic biomarker for response to the agent in non–small celll lung cancer.

Up to 12 Doses of Radium-223 Proven Safe in Bone-Metastatic Prostate Cancer

January 27th 2016

Retreatment with radium-223 dichloride (Xofigo) after initial therapy and progression was determined to be safe in patients with bone-metastatic castration-resistant prostate cancer.

Less May Be More: Refining HER2-Positive Breast Cancer Care

January 26th 2016

Mothaffar Rimawi, MD, discusses key recent data with HER2-targeted agents and the need to identify patients for whom optimal care may mean de-escalating therapy.

Radium-223 Benefits Survival, Not Just for Palliative Care

January 25th 2016

Phillip J. Koo, MD, discusses the benefits of radium-223 and why he thinks it is time the use of the drug becomes more widespread for the treatment of mCRPC, and potentially other cancers.

Tackling Challenging Patient Populations in DLBCL

January 21st 2016

Kathryn Kolibaba, MD, discusses the significance of the PYRAMID and other studies, and how she hopes the treatment paradigm for diffuse large b-cell lymphoma will evolve in the future.

NEXT PAGE
PREVIOUS PAGE